Ryan Strom, PA
Medical · Indianapolis, INNPI 1114335973
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 222 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 16.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,516, 6.2 times the $246 reported in 2021.
Across 222 payments — averaging $19.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$715
- Pfizer$587
- AbbVie$523
- Novo Nordisk$302
- GSK$237
- Otsuka America Pharmaceutical, Inc.$206
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,246100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 32 | $715 |
| Pfizer | 32 | $587 |
| AbbVie | 32 | $523 |
| Novo Nordisk | 19 | $302 |
| GSK | 17 | $237 |
| Otsuka America Pharmaceutical, Inc. | 9 | $206 |
| Lilly USA, LLC | 12 | $197 |
| Axsome Therapeutics, Inc. | 4 | $188 |
| Exact Sciences | 7 | $167 |
| Bayer | 9 | $155 |
| Merck | 6 | $107 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $92 |
| E.r. Squibb & Sons, L.L.C. | 5 | $87 |
| Radius Health, Inc. | 4 | $84 |
| Sumitomo Pharma America, Inc. | 3 | $73 |
| Amgen | 4 | $71 |
| Vanda Pharmaceuticals Inc. | 2 | $63 |
| Novartis | 3 | $55 |
| Astellas Pharma US Inc | 4 | $50 |
| Abbott | 2 | $50 |
| Dexcom, Inc. | 1 | $37 |
| Hologic Sales And Service, LLC | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| UCB, Inc. | 1 | $31 |
| Cranial Technologies, Inc | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Alvogen Inc | 1 | $17 |
| Abiomed | 1 | $16 |
| Boehringer Ingelheim | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,246 in reported general payments places this provider in the 85th percentile of 273 medical providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 85 | $117,176 |
| MounjaroTirzepatide | 59 | $95,729 |
| EliquisApixaban | 50 | $67,878 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $32,593 |
| XareltoRivaroxaban | 28 | $30,354 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $25,609 |
| FarxigaDapagliflozin Propanediol | 15 | $24,362 |
| JardianceEmpagliflozin | 25 | $22,939 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 42 | $9,374 |
| Varenicline Tartrate | 12 | $3,266 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 92 | $2,884 |
| Tamsulosin Hcl | 106 | $2,723 |
| Pantoprazole Sodium | 113 | $2,491 |
| Rosuvastatin Calcium | 99 | $2,377 |
| Adacel TdapDiph,pertuss(Acell),tet Vac/Pf | 32 | $2,345 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $197 | $212,905144 claims |
| PfizerEliquis | $587 | $67,87850 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $715 | $49,97151 claims |
| GSKTrelegy Ellipta, Shingrix | $237 | $41,96787 claims |
| Boehringer IngelheimJardiance | $13 | $22,93925 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 273 medical providers in Indiana.
Other medical in Indianapolis
- Meggie BeckleyIndianapolis$125K
- Jennifer ConnerIndianapolis$98K
- Jennifer IrwinIndianapolis$34K
- Andrew BurnsIndianapolis$13K
- Bridget WilliamsonIndianapolis$11K
- Lindsay MuellerIndianapolis$9K
- Meredith SlayterIndianapolis$8K
- Chelsea WilsonIndianapolis$5K
- Rachel SandersonIndianapolis$4K
- Amanda EckhardtIndianapolis$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.